QTTB Q32 Bio Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: QTTB

Price (delayed)

$25.665

Market cap

$82.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$35.1

Enterprise value

$44.94M

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Highlights
QTTB's debt has dropped by 96% year-on-year and by 95% since the previous quarter
QTTB's EPS is up by 14% from the previous quarter
QTTB's quick ratio has surged by 75% since the previous quarter but it is down by 8% year-on-year
Q32 Bio's gross profit has shrunk by 64% YoY and by 41% QoQ
Q32 Bio's revenue has plunged by 64% YoY and by 41% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.homologymedicines.com/

Key stats

What are the main financial stats of QTTB
Market
Shares outstanding
3.23M
Market cap
$82.89M
Enterprise value
$44.94M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.13
Price to sales (P/S)
71.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.88
Earnings
Revenue
$1.16M
EBIT
-$112.96M
EBITDA
-$110.32M
Free cash flow
-$95.9M
Per share
EPS
-$35.1
Free cash flow per share
-$29.85
Book value per share
$22.68
Revenue per share
$0.36
TBVPS
$26.32
Balance sheet
Total assets
$84.56M
Total liabilities
$11.57M
Debt
$1.32M
Equity
$72.99M
Working capital
$72.34M
Liquidity
Debt to equity
0.02
Current ratio
7.25
Quick ratio
7.14
Net debt/EBITDA
0.34
Margins
EBITDA margin
-9,543.1%
Gross margin
100%
Net margin
-9,771.7%
Operating margin
-8,774.1%
Efficiency
Return on assets
-76.3%
Return on equity
-104.5%
Return on invested capital
-108.5%
Return on capital employed
-154.8%
Return on sales
-9,771.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QTTB stock price

How has the Q32 Bio stock price performed over time
Intraday
-0.41%
1 week
-8.4%
1 month
20.55%
1 year
46.66%
YTD
134.6%
QTD
50.62%

Financial performance

How have Q32 Bio's revenue and profit performed over time
Revenue
$1.16M
Gross profit
$1.16M
Operating income
-$101.43M
Net income
-$112.96M
Gross margin
100%
Net margin
-9,771.7%
The operating margin has plunged by 111% YoY and by 39% from the previous quarter
Q32 Bio's gross profit has shrunk by 64% YoY and by 41% QoQ
Q32 Bio's revenue has plunged by 64% YoY and by 41% from the previous quarter
QTTB's net margin is down by 46% since the previous quarter

Growth

What is Q32 Bio's growth rate over time

Valuation

What is Q32 Bio stock price valuation
P/E
N/A
P/B
1.13
P/S
71.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.88
QTTB's EPS is up by 14% from the previous quarter
The P/B is 128% above the last 4 quarters average of 0.5 but 37% below the 5-year quarterly average of 1.8
QTTB's equity has dropped by 59% year-on-year and by 17% since the previous quarter
The P/S is 181% more than the last 4 quarters average of 25.5 but 44% less than the 5-year quarterly average of 128.8
Q32 Bio's revenue has plunged by 64% YoY and by 41% from the previous quarter

Efficiency

How efficient is Q32 Bio business performance
QTTB's ROS is down by 46% from the previous quarter
Q32 Bio's return on invested capital has decreased by 20% QoQ
The ROA has contracted by 7% from the previous quarter
The return on equity has declined by 7% since the previous quarter

Dividends

What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QTTB.

Financial health

How did Q32 Bio financials performed over time
The total liabilities has plunged by 78% from the previous quarter and by 77% YoY
QTTB's quick ratio has surged by 75% since the previous quarter but it is down by 8% year-on-year
QTTB's debt is 98% smaller than its equity
QTTB's debt has dropped by 96% year-on-year and by 95% since the previous quarter
Q32 Bio's debt to equity has plunged by 94% from the previous quarter and by 88% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.